Drug intelligence / Profile preview

anti-gingipain egg yolk antibodies

Development stage
Unknown
Lead developer
Nihon University School of Dentistry
Modality
Antibody-Based Therapeutics
Administration
Oral, Topical
01

Overview

Anti-gingipain egg yolk antibodies (IgY-GP) are avian-derived polyclonal immunoglobulin Y (IgY) antibodies raised in laying hens immunized with purified gingipains from *Porphyromonas gingivalis*, a key Gram-negative anaerobic bacterium implicated in the pathogenesis of periodontal disease. The active ingredient targets the gingipain family of cysteine proteinases (specifically the Arg-X and Lys-X cysteine proteinases, Rgp and Kgp), which are critical virulence factors involved in bacterial colonization, tissue destruction, and immune evasion. Developed by the Nihon University School of Dentistry, IgY-GP is designed as a passive immunization strategy for periodontal disease. It is formulated as locally retained oral tablets or subgingival gels used adjunctively after scaling and root planing (SRP) to inhibit gingipain activity, reduce pocket depth, and decrease bleeding on probing.

Other names
IgY-GPanti-gingipain IgYanti-Porphyromonas gingivalis egg yolk antibodyanti-P. gingivalis egg yolk antibody against gingipainsanti-gingipain egg yolk antibody
02

Targets

Kgp (Lysine gingipain)Rgp (Arginine gingipain)Kgp/Rgp (Gingipain cysteine endopeptidase)

Beyond the preview

Go deeper on anti-gingipain egg yolk antibodies.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-gingipain egg yolk antibodies.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call